GeoVax Gains EMA Support for Streamlined Mpox and Smallpox Vaccine Development

GeoVax Labs, Inc., a clinical-stage biotechnology company, has achieved a pivotal milestone with the European Medicines Agency (EMA) endorsing a streamlined development pathway for its GEO-MVA vaccine, aimed at preventing Mpox and smallpox. This regulatory guidance confirms that a single Phase 3 immuno-bridging trial could suffice for evaluating the vaccine's efficacy and supporting a Marketing Authorization Application (MAA), potentially accelerating the approval process.

The EMA's Committee for Medicinal Products for Human Use (CHMP) agreed with GeoVax's proposed strategy, including the omission of Phase 1 and Phase 2 trials, based on the adequacy of non-clinical studies. This development is timely, as the World Health Organization recently declared Mpox a Public Health Emergency of International Concern, underscoring the urgent need for diversified vaccine sources amid rising cases and strained global supplies.

David Dodd, Chairman and CEO of GeoVax, highlighted the significance of this regulatory advancement, noting the potential of GEO-MVA to enhance global health resilience by providing an alternative to the current single-supplier scenario. The vaccine's development is particularly critical given the emergence of highly virulent Mpox strains and the detection of the virus in wastewater across multiple U.S. states, signaling widespread transmission risks.

GeoVax's initiative to transition to a next-generation manufacturing platform promises scalable and cost-effective production, aiming to ensure vaccine accessibility and self-sufficiency, especially in regions like Africa. This regulatory progress not only brings GeoVax closer to addressing immediate public health needs but also strengthens long-term preparedness against Mpox and smallpox threats.